Pan­el of neu­ro­science ex­perts lays out the com­pli­ca­tions with us­ing Bio­gen's new Alzheimer's drug

Treat­ment of ear­ly Alzheimer’s pa­tients with Bio­gen’s new drug Aduhelm should close­ly re­sem­ble how the drug was stud­ied in its piv­otal clin­i­cal tri­als, ac­cord­ing to new rec­om­men­da­tions from a pan­el of neu­ro­science ex­perts led by UN­LV’s Jef­frey Cum­mings.

“Those con­sid­er­ing ad­u­canum­ab ther­a­py should un­der­stand that the ex­pect­ed ben­e­fit is slow­ing of cog­ni­tive and func­tion­al de­cline; im­prove­ment of the cur­rent clin­i­cal state is not an­tic­i­pat­ed,” they wrote Tues­day in The Jour­nal of Pre­ven­tion of Alzheimer’s Dis­ease, not­ing that some of their rec­om­men­da­tions are more spe­cif­ic or more re­stric­tive than the in­for­ma­tion pro­vid­ed in the FDA’s pre­scrib­ing in­for­ma­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.